Holen Sie sich die Stockscreener-App
62.37
1.40%
-0.485
Schlusskurs vom Vortag:
$62.85
Offen:
$62.37
24-Stunden-Volumen:
8,750
Relative Volume:
0.01
Marktkapitalisierung:
$2.91B
Einnahmen:
$1.35B
Nettoeinkommen (Verlust:
$163.34M
KGV:
19.04
EPS:
3.2763
Netto-Cashflow:
$189.17M
1W Leistung:
-4.18%
1M Leistung:
+7.77%
6M Leistung:
+15.88%
1J Leistung:
-9.27%
1-Tages-Spanne:
$62.37
$63.47
1-Wochen-Bereich:
$61.58
$65.10
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
62.72 | 2.98B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
109.98 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
356.32 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.70 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.78 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.33 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics launches recruitment drive to expand clinical support roles - Traders Union
Assessing Haemonetics (HAE) Valuation After Recent Share Price Pullback - Yahoo Finance
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack - Yahoo Finance
A Review of Q4 Earnings for Medical Devices & Supplies Specialty Stocks: Comparing Haemonetics (NYSE:HAE) to Its Competitors - Bitget
Haemonetics Wins FDA Nod For Persona PLUS Plasma Growth Opportunity - simplywall.st
Haemonetics Corporation $HAE Shares Sold by Fisher Asset Management LLC - MarketBeat
Haemonetics Repays $300 Million Convertible Senior Notes Due 2026 - marketscreener.com
William Blair Investment Management LLC Buys 57,332 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp repays outstanding 0.00% convertible senior notesSEC filing - marketscreener.com
Haemonetics repays $300 million convertible notes at maturity By Investing.com - Investing.com Canada
Haemonetics repays $300 million convertible notes at maturity - Investing.com
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure - TipRanks
Haemonetics repays $300M 0.00% convertible notes due 2026 in cash - TradingView
Assessing Haemonetics (HAE) Valuation After FDA Clearance Of NexSys PCS Persona PLUS System - simplywall.st
3 Reasons HAE is Risky and 1 Stock to Buy Instead - Finviz
Haemonetics at Raymond James: Strategic Growth and Challenges - Investing.com Nigeria
Haemonetics at Raymond James: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Royce & Associates LP Sells 569,815 Shares of Haemonetics Corporation $HAE - MarketBeat
Vanguard Group Inc. Reduces Stock Position in Haemonetics Corporation $HAE - MarketBeat
Kestrel Investment Management Corp Purchases New Shares in Haemonetics Corporation $HAE - MarketBeat
Ameritas Investment Partners Inc. Has $636,000 Holdings in Haemonetics Corporation $HAE - MarketBeat
Is Haemonetics (HAE) Offering A Compelling Entry Point After Prolonged Share Price Weakness - simplywall.st
Haemonetics Corporation $HAE Stake Lessened by Citigroup Inc. - MarketBeat
Q1 EPS Estimates for Haemonetics Decreased by Zacks Research - MarketBeat
Fox Run Management L.L.C. Takes $1.36 Million Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Completes Hemerus Medical Acquisition - Yahoo
Zacks Research Forecasts Increased Earnings for Haemonetics - MarketBeat
Therapeutic Apheresis Market to Reach US$ 6,009.58 Million - openPR.com
Haemonetics (HAE) Is Up 5.3% After FDA Clears NexSys PCS With Persona PLUS Technology - simplywall.st
Haemonetics receives FDA clearance for plasma collection system - Investing.com
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology - PR Newswire
Clark Estates Inc. NY Takes $2.24 Million Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics receives FDA clearance for plasma collection system By Investing.com - Investing.com Canada
Haemonetics Stock After Earnings: Quiet Breakout or Value Trap? - AD HOC NEWS
Isthmus Partners LLC Acquires 16,505 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference - PR Newswire
Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Haemonetics Corporation $HAE Stock Holdings Lessened by Heartland Advisors Inc. - MarketBeat
ABN Amro Investment Solutions Buys Shares of 200,000 Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 - Finviz
Growth Recap: Will Haemonetics Corporation outperform its industry peersJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Assessing Haemonetics (HAE) Valuation After Recent Share Price Weakness - Yahoo Finance
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth - Yahoo Finance
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 21.7% - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Principal Financial Group Inc. - MarketBeat
Haemonetics Releases 2024-2025 Corporate Responsibility Report - The Globe and Mail
Haemonetics (HAE) Balances Softer Interventional Sales With Buybacks – What Story Does Guidance Tell? - simplywall.st
5 Revealing Analyst Questions From Haemonetics's Q4 Earnings Call - Finviz
5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call - FinancialContent
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):